Companies / Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc.

Nasdaq: AARDCIK 1774857SAN DIEGO, CA

Financials

Revenue—
Net income$-57.59M
Total debt—
Cash$73.85M
Diluted EPS$-2.93
Shares outstanding21.9M

Ownership

21.9M shares outstanding · as of Jul 31, 2026
47.4%Institutions
Ownership
Institutions47.38%10,369,999
Public float52.62%11,514,847

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 3

View all →
Insider% of sharesShares
Jaiman ManasiChief Medical Officer
——
Lee Tien-LiCEOChief Executive Officer · Director · 10% owner
——
Sun NelsonChief Financial Officer
——

Institutional holders 74

View all →
HolderValue% of shares
Decheng Capital LLC$51.41M17.90%
Citadel Advisors LLC$16.92M5.89%
Vanguard Group Inc$9.42M3.28%
SymBiosis Capital Partners, LLC$6.26M2.18%
SilverArc Capital Management, LLC$3.99M1.39%
Laurion Capital Management LP$3.90M4.73%
Cresset Asset Management, LLC$1.88M0.65%
Centiva Capital, LP$1.28M0.45%
Northern Trust Corp$1.17M0.41%
Geode Capital Management, LLC$1.17M1.41%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Feb 9, 2026Sun Nelson
Executive
GrantStock option (right to buy)—-71K
-50.00%
70,549
0.32% of shares
low
Feb 9, 2026Lee Tien-Li
CEO
GrantStock option (right to buy)—-204K
-50.00%
203,851
0.93% of shares
low
Feb 9, 2026Jaiman Manasi
Executive
GrantStock option (right to buy)—-71K
-50.00%
70,549
0.32% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
AARDCommon StockEquity002942100BBG01223DLB2